Clinical trial Recruiting at 1 site Observational

Early recognition and treatment strategies for fibrotic interstitial lung disease in China

Official title: Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

Run by China-Japan Friendship Hospital · NCT06655090 · Data updated 2026-11-12

This study is trying to find better ways to recognize and treat fibrotic interstitial lung disease in China by looking at a large group of patients and testing new methods for diagnosis and treatment.

More Interstitial Lung Disease (ILD) trials

Quick facts

Study typeObservational
SexAll
Enrollment10000 (estimated)
SponsorChina-Japan Friendship Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedDecember 1, 2021
Main results expectedNovember 30, 2024
Study endsNovember 30, 2027
Registry record updatedOctober 23, 2024
Trial IDNCT06655090 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with interstitial lung disease.

Probably not a fit

Patients who lack a chest CT or refuse to participate will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to create a large cohort of over 10,000 cases of fibrotic interstitial lung disease (f-ILD), including a significant number of pneumoconiosis cases, to study clinical phenotypes associated with pulmonary fibrosis. The study will evaluate the safety and effectiveness of various biopsy techniques and optimize histological diagnosis methods for f-ILD. Additionally, it will develop an artificial intelligence system for assessing the severity of pulmonary fibrosis and identify important molecular targets and biomarkers. The ultimate goal is to establish early recognition models and intervention strategies for f-ILD that can be applied nationwide.

Why it matters

Potential benefit: If successful, this study could lead to improved early detection and treatment strategies for patients with fibrotic interstitial lung disease.

How similar studies have gone: Other studies have shown success in utilizing similar approaches for early recognition and treatment of interstitial lung diseases, indicating potential for this study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed as ILD

Exclusion Criteria:

* Lack of chest CT
* Patients refused to participant

Where it's running

  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.